Skip NavigationSkip to Content
Return Return to Search Results

Antitumor agents. 192. Antitubulin effect and cytotoxicity of C(7)-oxygenated allocolchicinoids

  1. Author:
    Guan, J.
    Zhu, X. K.
    Brossi, A.
    Tachibana, Y.
    Bastow, K. F.
    Verdier-Pinard, P.
    Hamel, E.
    McPhail, A. T.
    Lee, K. H.

  2. Author Address

    Lee KH Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Nat Prod Lab Chapel Hill, NC 27599 USA Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Nat Prod Lab Chapel Hill, NC 27599 USA NCI, Lab Drug Discovery Res & Dev, Dev Therapeut Program, Frederick Canc Res & Dev Ctr Frederick, MD 21702 USA Duke Univ, Paul M Gross Chem Lab Durham, NC 27708 USA
    1. Year: 1999
  2. Journal: Collection of Czechoslovak Chemical Communications
    1. 64
    2. 2
    3. Pages: 217-228
  4. Type of Article: Article
  1. Abstract:

    Two allocolchicinoids 6 and 8, prepared from colchicine, together with allo compounds 9-11, made from 6 by reduction and regiodemethylation, were evaluated for antitubulin and antitumor activities. Structures of 6, 8, and 10 were confirmed by X-ray crystallographic analysis. Compounds 6, 8, and 9 have high tubulin binding affinity and display potent inhibitory activities against tubulin polymerization and solid human tumor cell lines. Particularly, drug-resistant KB cell lines, including KB-7d, KB-VCR, and KB-CPT, do not show marked resistance to these compounds. [References: 23]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel